Ironshore Pharmaceuticals secures US $200M financing

Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., has raised US $200 million by way of private placement of 13% Senior Secured Notes due 2024.

Canadian investors subscribed ##subscriber ONLY content## million of the private placement.

Morgan Stanley & Co. LLC acted as sole placement agent for the transaction. Goodmans LLP acted as Lead Counsel, Morrison & Foerster LLP acted as U.S. counsel and Solomon Harris acted as Cayman Islands counsel for Ironshore.

Based in Cayman Islands, Ironshore Pharmaceuticals & Development, Inc. is a pharmaceutical company that is leveraging its proprietary technology, DELEXIS, to optimize the delivery of previously approved drug products.

photo credit: Ironshore Pharmaceuticals & Development

Ted Liu

Ted Liu, M.Sc. (Mining, Queen's), MBA (Finance, Toronto), is the Editor of Private Capital Journal,,, and the former Editor of Canadian Private Equity. Ted has been passionately tracking Canadian private capital industry since 1992, having most recently served as Research Director for The Canadian Venture Capital and Private Equity Association (CVCA).

Ted is the architect of CVCA infobase, and is the architect of CPE Media's, Canada's most sophisticated and advanced all private capital and public market financing database.